Foamix Pharmaceuticals

Foamix has a strong in-house pipeline of drugs for dermatologic, ophthalmologic and gynecologic indications. The Company’s lead product under development is the first-in-class Topical Minocycline Foam addressing large markets in dermatology and ophthalmology. Minocycline foam demonstrated high efficacy and favorable safety in two phase II clinical studies in Acne and Impetigo patients.  Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burns as well as ophthalmic disorders.

Foamix Pharmaceuticals Ltd (FOMX) CEO Dave Domzalski on Q4 2020 Results - Earnings Call Transcript

Foamix Pharmaceuticals Ltd (FOMX) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript

REHOVOT, Israel and BRIDGEWATER, N.J., Feb.  18, 2020  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults. The new data have been presented at the 17th Annual South Beach Symposium in Dermatology held on February 6-9, 2020 in Miami, Florida.

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

Transaction on Track to Close in early March 2020 Transaction on Track to Close in early March 2020

Foamix and Menlo  Announce Shareholder Approval of Proposed Merger

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

REHOVOT, Israel, and BRIDGEWATER, N.J., Feb.  06, 2020  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the  Journal of the American Academy of Dermatology  (JAAD).  Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam), which is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults.

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

REHOVOT, Israel, and BRIDGEWATER, N.J., Jan.  17, 2020  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a  press release  issued on January 16, 2020. Perceptive Advisors LLC, the Company’s largest shareholder, previously signed a voting agreement on November 10, 2019 to vote its Foamix shares in favor of the merger at the meeting.

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies

Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Menlo Therapeutics

Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Earnings & Merger Announcement with Menlo Therapeutics Conference (Transcript)

Investors take a close look at Foamix's new acquisition -- and don't like what they see.

Why Foamix Stock Just Dropped 27.5%

Shares of Menlo Therapeutics Ltd. MNLO, -9.09% was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. FOMX, -27.53% plunged 16%, after the company's announced a merger in which Foamix acquired Menlo in an all-stock deal.

Menlo, Foamix stocks set for selloffs after all-stock merger deal

Foamix (FOMX) delivered earnings and revenue surprises of -20.59% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Foamix (FOMX) Reports Q3 Loss, Misses Revenue Estimates

Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

REHOVOT, Israel and BRIDGEWATER, N.J., Nov.  04, 2019  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05 (Studies 04 & 05) in the  Journal of Clinical and Aesthetic Dermatology (JCAD). Studies 04 and 05 were conducted by Foamix to support the New Drug Application submission of AMZEEQ™ (minocycline) topical foam, which was approved by the U.S. Food and Drug Administration (FDA) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

Foamix Pharmaceuticals' FDA Application Accepted For Review, Catalyst Laid Out Ahead

Will Foamix (FOMX) Report Negative Q3 Earnings? What You Should Know

Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed

Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103

Alexion Pharma

AstraZeneca

The FDA has cleared three therapies since Friday, sending shares of the sponsor companies higher Monday morning.

3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline

UPDATE -- Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

PDUFA Target Action Date of June 2nd, 2020 PDUFA Target Action Date of June 2nd, 2020

Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

Foamix’s PDUFA date is October 20th for FMX101. I plan to trade a portion of my position. However, I am willing to hold the remaining shares for the long term.

Foamix Pharmaceuticals: Managing My Position Around FMX101's PDUFA

REHOVOT, Israel and BRIDGEWATER, N.J., Oct.  10, 2019  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company, today announced it will present results from nine clinical trials in five posters relating to its investigational topical product candidates FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults, at the 39th Annual Fall Clinical Dermatology Conference® October 17-20 in Las Vegas, Nevada.

Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

Fiverr

Philip Morris

According to the latest Bank of America Corp. (BAC) survey, the risk of a near-term recession is now at a multi-year high.

3 Stocks for the Next Recession

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

News for Foamix Pharmaceuticals Stock (FOMX)